|drug2993||Placebo-LDE phase 2 Wiki||1.00|
|drug2360||Methotrexate-LDE phase 1 Wiki||1.00|
|drug2361||Methotrexate-LDE phase 2 Wiki||1.00|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Safety and immunogenicity one-month study in healthy individuals administered once-daily pill of therapeutic vaccine made from heat-inactivated plasma from donors with COVID-19. Healthy, at least 20, volunteers will be monitored for signs of adverse events. Their PBMC will be collected at baseline and one month later to analyze which type of immune response vaccine has induced.
Description: Routine laboratory complete blood cell count at pre- and post-treatment periods by automated CBC counter Routine laboratory complete blood count Routine clinical laboratory CBC parameters at pre- and post-treatment periodsMeasure: Effect on CBC as per CTCAE v4.0 Time: 15 Days
Description: Routine clinical laboratory blood biochemistry parameters at pre- and post-treatment periods by automated biochemistry analyzerMeasure: Effect on biochemistry parameters as per CTCAE v4.0 Time: 15 Days
Description: Clinical well-being assessed by CTCAE v4.0Measure: Lack of adverse events as per CTCAE v4.0 Time: 15 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports